Intellia Therapeutics Inc (NTLA) Expected to Announce Earnings of -$0.48 Per Share
Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings per share (EPS) of ($0.48) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Intellia Therapeutics’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.46). Intellia Therapeutics posted earnings of ($0.31) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 54.8%. The company is expected to report its next earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($1.73) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($1.71). For the next financial year, analysts anticipate that the company will report earnings of ($2.25) per share, with EPS estimates ranging from ($2.34) to ($2.16). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Intellia Therapeutics.
NTLA has been the subject of several research reports. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. ValuEngine cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, December 12th. BidaskClub cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Finally, TheStreet cut Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $30.17.
Large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $146,000. Nationwide Fund Advisors raised its holdings in shares of Intellia Therapeutics by 117.7% in the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after acquiring an additional 4,351 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Intellia Therapeutics by 61.3% in the 3rd quarter. SG Americas Securities LLC now owns 10,169 shares of the company’s stock valued at $253,000 after acquiring an additional 3,863 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $167,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $230,000. 68.14% of the stock is currently owned by hedge funds and other institutional investors.
Intellia Therapeutics (NASDAQ:NTLA) opened at $27.48 on Friday. Intellia Therapeutics has a 12 month low of $11.15 and a 12 month high of $33.34.
COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics Inc (NTLA) Expected to Announce Earnings of -$0.48 Per Share” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-expected-to-announce-earnings-of-0-48-per-share/1909704.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.